Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients With Advanced Solid Tumours

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours

Inclusion Criteria:

• Histological or cytological diagnosis of advanced solid tumour for which no suitable effective therapy exists;
• Evaluable disease
• Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

• Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry; major surgery with 4 weeks of entering the study
• Heavily pre treated patient > 2 previous chemotherapy regimens for metastatic disease
• Co-existing active infection